Full Length Research Paper
References
Adolescents PoAGfAa (2008). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Services DoHaH, Washington, DC. |
|
Adolescents PoAGfAa (2011). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (DHHS) 1-166. |
|
Ansari PP, Ansari N (2008). Acute renal failure in an AIDS patient on tenofovir: a case report. Journal of Medical Case Reports 2(1):94. |
|
compared with nucleoside reverse-transcriptase inhibitor treatment. Clinical Infectious Diseases 40(8):1194-8. |
|
Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clinical Infectious Diseases 51(5):496-505. |
|
FBaGS (2005). Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 19(1):93-9. |
|
Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H (2007). Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral therapy, 12(8):1165. |
|
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study Group (2004). Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. Jama 292(2):191-201. |
|
Gallant JE, Parish MA, Keruly JC, Moore RD (2005). Changes in renal function associated with tenofovir disoproxil fumarate treatment, |
|
Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S, California Collaborative Treatment Group 578 (2008). Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. The Journal of infectious diseases 197(1):102-108. |
|
HAPCO/MOH F (2008). Guideline for the management of opportunistic infections and antiretroviral treatment in adolescent and adults in Ethiopia. |
|
Hassane I, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, Launay-Vacher V, Deray G (2004). Renal safety of tenofovir in HIV treatment-experianced patients AIDS 18(7):1074-6. |
|
HIV medicine (2007). |
|
Jim Younga, Schäfer J, Fux CA, Furrer H, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC (2012). Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 26(5):567-75. |
|
Joel EG, Moore RD (2005). Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS (Londan ,England) 23(15):1971-5 |
|
Joel EG, Moore RD (2009). Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS (Londan, England) 23(15):1971. |
|
Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, Gazzard B (2004). Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. JAIDS Journal of Acquired Immune Deficiency Syndromes 37(4):1489-95. |
|
KDIGO (2012). Clinical practice guideline for the evaluation and management of chronic kidney disease 3(1). |
|
Ketan Kk, Patel AK, Ranjan RR, Patel AR, Patel JK (2010). Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian Journal sexual transmited diseasse 31(1):30. |
|
Laprise C, Baril JG, Dufresne S, Trottier H (2013). Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clinical infectious diseases 56(4):567-78. |
|
Michael H, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry Jr C, Klein D. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients (2010). Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 53(1):62-69. |
|
Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren, J.D. and EuroSIDA Study Group (2010).Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24(11):1667-78. |
|
Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S (2007). The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21(10):1273-1281. |
|
Paul OD, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, Palella Jr FJ (2011). Low incidence of renal impairment observed in tenofovir-treated patients. Journal of antimicrobial chemotherapy 66(5):1120-1126. |
|
Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Céron D. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. Journal of Acquired Immune Deficiency Syndromes 35(3):269-73. |
|
Post FA (2010). Biomarkers of impaired renal function. Current Opinion in HIV and AIDS 5(6):524-30. |
|
Sasisopin K, Chaisiri K, Kasettratat N, Visuttimak P, Bowonwatanuwong C (2011). Monitoring of Renal Function among HIV-Infected Patients Receiving Tenofovir in a Resource-limited setting. Journal of the International Association of Physicians in AIDS Care (JIAPAC) 10(5):297-302. |
|
Scherzer R, Estrella M, Yongmei LI, Deeks SG, Grunfeld C, Shlipak MG (2012). Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26(7):867-75. |
|
UNAIDS (2013). HIV and AIDS Estimate RSTESA. |
|
Wandeler G, Lloyd M, Musonda P, Mwango A, Vinikoor MJ, Davies MA., Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, (2014). Effect of Baseline Renal Function on Tenofovir-Containing Antiretroviral Therapy Outcomes in Zambia. Clinical Infectious Diseases 58(10):1473-1480. |
|
WHO (2007). AIDS epidemic update. Geneva. |
|
WHO (2010). Antiretroviral therapy for HIV infection in adults and adolescents. recommendations for a public health approach-2010 revision. World Health Organization. |
|
Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G (2006). Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clinical Infectious Diseases 42(2):283-90. |
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0